retatrutide phase 2 trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished New GLP-3 drug significantly slashes

Lemonaid was excluded from Regenerons acquisition of 23andMes assets, leaving its current ownership and long-term operational continuity uncertain

However, the ongoing treatment costs for these medications raise concerns about the sustainability of their widespread use in the healthcare system, especially given the risk of weight regain without continued use

One of the medications that may be included in a patients treatment plan is Ozempic , which contains the active ingredient semaglutide

As mentioned above, tirzepatide hasnt been compared to the higher dose of semaglutide (Wegovy) now available

At 500 mcg/dose: 20 doses

At Doctor Tony Clinic, we recommend starting with a lower dosage and gradually increasing it as your body becomes accustomed to the treatment